文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

乌帕替尼与华法林相互作用致INR显著升高:病例报告与文献回顾

Upadacitinib and Warfarin Drug Interaction Resulting in Significantly Increased International Normalized Ratio: A Case Report and Review of the Literature.
PubMed 文献 · Am J Health Syst Pharm · 2026-10-22

一例41岁女性机械二尖瓣置换术后长期华法林抗凝(目标INR 2.5-3.5)患者,启动乌帕替尼15 mg约一周后INR升至9.3,停药后恢复;数周后再次服用两剂乌帕替尼,INR升至4.7。提示JAK抑制剂与华法林可能存在说明书未载明的相互作用。

要点

  • 华法林抗凝患者启动乌帕替尼后应密切监测INR。
  • 该相互作用未见于乌帕替尼说明书,机制尚不明确。
  • 疑似发生时应停用乌帕替尼并按INR升高处理。

核心结论

  • 乌帕替尼与华法林合用可导致INR显著升高,属说明书未载明的潜在相互作用。

研究设计与样本

  • 单例病例报告并复习文献:41岁女性,机械二尖瓣置换术后华法林抗凝,目标INR 2.5-3.5。

主要发现

  • 合用乌帕替尼15 mg与华法林近一周、无其他药物或食物变化,INR升至9.3,予口服维生素K后恢复。
  • 数周后因特应性皮炎症状再服两剂乌帕替尼,INR升至4.7。
  • 停用乌帕替尼并调整华法林剂量后INR恢复正常,特应性皮炎治疗更换。

临床怎么用

  • 接受全身抗凝的患者启动JAK抑制剂时应警惕INR升高的矛盾效应并加强监测。

局限性

  • 为单例病例报告,相互作用机制尚未阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe a case report of upadacitinib interaction with warfarin, resulting in a supratherapeutic international normalized ratio (INR). SUMMARY: A 41-year-old female with a history of severe refractory atopic dermatitis was initiated on upadacitinib, a Janus kinase (JAK) inhibitor. She additionally had a history of mechanical mitral valve replacement for which she was maintained on warfarin with a target INR of 2.5-3.5. After nearly a week of concomitant upadacitinib 15 mg and warfarin, with no other changes in medications or food, her INR increased to 9.3, for which she was sent to the emergency department and received oral vitamin K. Her INR returned to baseline and upadacitinib was discontinued. Several weeks later, due to refractory atopic dermatitis symptoms, she took another two doses of upadacitinib and her INR increased to 4.7. She was instructed to take no further upadacitinib, her INR subsequently normalized with warfarin dose modification, and her atopic dermatitis therapy was changed. CONCLUSION: Upadacitinib labeling does not include interaction with systemic anticoagulation nor increases in INR. The mechanism of this interaction remains to be elucidated, but an imbalance in pro-thrombotic and anti-thrombotic activity from various downstream cytokine inhibition may play a role. Clinicians should be aware of this potential paradoxical effect in patients on systemic anticoagulation who are initiating JAK inhibitors.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Buscemi L, Revankar R, Bryer B, et al. Upadacitinib and Warfarin Drug Interaction Resulting in Significantly Increased International Normalized Ratio: A Case Report and Review of the Literature. Am J Health Syst Pharm. 2026. PMID: 42910612. doi:10.1093/ajhp/zxag350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。